Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 19, Issue 5-6, 2018, Pages 377-386

  Espejo Porras, Francisco ^a,b,c   Fernández Ruiz, Javier ^a,b,c   de Lago, Eva ^a,b,c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

Author keywords

amyotrophic lateral sclerosis; CB1 and CB2 receptors; FAAH and MAGL enzymes; Motor neuron disease; post mortem tissues

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CHOLINE ACETYLTRANSFERASE; ENZYME; FATTY ACID AMIDASE; GLIAL FIBRILLARY ACIDIC PROTEIN; MAGL ENZYME; TAR DNA BINDING PROTEIN; UNCLASSIFIED DRUG; ENDOCANNABINOID; MAP2 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; AUTOPSY; BRAIN CELL; FEMALE; GLIOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOTONEURON; MOTOR CORTEX; MOTOR NEURON DISEASE; NERVE CELL NECROSIS; NISSL STAINING; PRIORITY JOURNAL; SPINAL CORD; VERY ELDERLY; WESTERN BLOTTING; METABOLISM; PATHOLOGY; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; AUTOPSY; ENDOCANNABINOIDS; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MOTOR CORTEX; RECEPTORS, CANNABINOID; SPINAL CORD; UNITED KINGDOM;

EID: 85041127711     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.1080/21678421.2018.1425454     Document Type: Article

References (38)

1. Hardiman O, van den Berg LH, Kiernan MC., Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7:639–49.
2. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59–62.
3. Buratti E, Baralle FE., The multiple roles of TDP-43 in pre-mRNA processing and gene expression regulation. RNA Biol. 2010;7:420–9.
4. Lagier-Tourenne C, Polymenidou M, Cleveland DW., TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Genet. 2010;19:R46–64.
5. Cruts M, Gijselinck I, Van Langenhove T, van der Zee J, Van Broeckhoven C., Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum. Trends Neurosci. 2013;36:450–9.
6. Al-Chalabi A, Hardiman O., The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9:617–28.
7. Renton AE, Chiò A, Traynor BJ., State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17:17–23.
8. Bova MP, Kinney GG., Emerging drug targets in amyotrophic lateral sclerosis. Expert Opin Orphan Drugs. 2013;1:5–20.
9. Habib AA, Mitsumoto H., Emerging drugs for amyotrophic lateral sclerosis. Expert Opin Emerg Drugs. 2011;16:537–58.
10. Rothstein JD., Edaravone: a new drug approved for ALS. Cell. 2017;171:725
11. Bilsland LG, Nirmalananthan N, Yip J, Greensmith L, Duchen MR., Expression of mutant SOD1 in astrocytes induces functional deficits in motoneuron mitochondria. J Neurochem. 2008;107:1271–83.
12. de Lago E, Moreno-Martet M, Espejo-Porras F, Fernández-Ruiz J., Endocannabinoids and amyotrophic lateral sclerosis. In: Fattore L, Editor. Cannabinoids in Neurologic and Mental Disease. The Netherlands: Elsevier; 2015:99–124.
13. Clemente S., Amyotrophic lateral sclerosis treatment with ultramicronized palmitoylethanolamide: a case report. CNS ND-DT. 2012;11:933–6.
14. Raman C, McAllister SD, Rizvi G, Patel SG, Moore DH, Abood ME., Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph. Lateral Scler Other Motor Neuron Disord. 2014;5:33–9.
15. Weydt P, Hong S, Witting A, Möller T, Stella N, Kliot M. Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:182–4.
16. Bilsland LG, Dick JR, Pryce G, Petrosino S, Di Marzo V, Baker D, et al. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. Faseb J. 2006;20:1003–5.
17. Kim K, Moore DH, Makriyannis A, Abood ME., AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol. 2006;542:100–5.
18. Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem. 2007;101:87–98.
19. Fernández-Ruiz J, Romero J, Velasco G, Tolón RM, Ramos JA, Guzmán M. Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci. 2007;28:39–45.
20. Fernández-Ruiz J, Moro MA, Martínez-Orgado J., Cannabinoids in neurodegenerative disorders and stroke/brain trauma: from preclinical models to clinical applications. Neurotherapeutics. 2015;12:793–806.
21. Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C, Coates JR, Pérez-Díaz C, de Lago E, et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 2006;6:12.
22. Moreno-Martet M, Espejo-Porras F, Fernández-Ruiz J, de Lago E., Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex®-like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis. CNS Neurosci Ther. 2014;20:809–15.
23. Fernández-Trapero M, Espejo-Porras F, Rodríguez-Cueto C, et al. Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis. Dis Model Mech. 2017;10:551–8.
24. Espejo-Porras F, Piscitelli F, Verde R, Ramos JA, Di Marzo V, de Lago E, et al. Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders. J Neuroimmune Pharmacol. 2015;10:233–44.
25. Iannotti FA, Di Marzo V, Petrosino S., Endocannabinoids and endocannabinoid-related mediators: targets, metabolism and role in neurological disorders. Prog Lipid Res. 2016;62:107–28.
26. Lambert DM, Di Marzo V., The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? Curr Med Chem. 1999;6:757–73.
27. Alvarez FJ, Lafuente H, Rey-Santano MC, Mielgo VE, Gastiasoro E, Rueda M, et al. Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Pediatr Res. 2008;64:653–8.
28. Rodríguez-Cueto C, Benito C, Romero J, Hernández-Gálvez M, Gómez-Ruiz M, Fernández-Ruiz J., Endocannabinoid-hydrolysing enzymes in the post-mortem cerebellum of humans affected by hereditary autosomal dominant ataxias. Pathobiology. 2014;81:149–59.
29. Rodríguez-Cueto C, Benito C, Fernández-Ruiz J, Romero J, Hernández-Gálvez M, Gómez-Ruiz M., Changes in CB1 and CB2 receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias. Br J Pharmacol. 2014;171:1472–89.
30. Shi SR, Cote RJ, Taylor CR., Antigen retrieval techniques: current perspectives. J Histochem Cytochem. 2001;49:931–7.
31. Schnell SA, Staines WA, Wessendorf MW., Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue. J Histochem Cytochem. 1999;47:719–30.
32. Witting A, Weydt P, Hong S, Kliot M, Moller T, Stella N. Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. J Neurochem. 2004;89:1555–7.
33. Atwood BK, Mackie K., CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol. 2010;160:467–79.
34. Van Sickle MD, Duncan M, Kingsley PJ, Chessell IP, Naylor A, Bountra C, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005;310:329–32.
35. Skaper SD, Buriani A, Dal Toso R, et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci USA. 1996;93:3984–9.
36. 2 receptors in human nigral neurons that degenerate in Parkinson's disease. Neurosci Lett. 2015;587:1–4.
37. Sierra S, Luquin N, Rico AJ, Gómez-Bautista V, Roda E, Dopeso-Reyes IG, et al. Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism. Brain Struct Funct. 2015;220:2721–38.
38. Lanciego JL, Barroso-Chinea P, Rico AJ, Conte-Perales L, Callén L, Roda E, et al. Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis. J Psychopharmacol (Oxford). 2011;25:97–104.